Sensus Healthcare Reports 59% Q1 Revenue Drop, Credit Facility Terminated
SRTS sits 24% above its 52-week low of $2.82 on light trading volume (0.4× avg).
Summary
Sensus Healthcare reported a 59% year-over-year revenue decline and increased net loss for Q1 2026, compounded by the upcoming termination of its $15 million credit facility, raising significant liquidity concerns.
Key Events · Earnings and Guidance · SRTS
-
Revenue Plummets 59%
Q1 2026 revenue decreased by 59% year-over-year to $3.4 million, primarily due to lower unit sales and a shift to Fair Deal Agreement and rental programs where revenue is recognized over time.
-
Credit Facility Terminated
The company's $15 million revolving credit facility will terminate on May 20, 2026, following a default on profitability covenants. This significantly impacts liquidity and future funding options.
-
Increased Net Loss and Reduced Gross Margin
Net loss for Q1 2026 increased slightly to $2.6 million, and the gross profit margin sharply declined from 53.0% in Q1 2025 to 29.4% in Q1 2026, reflecting product mix changes and upfront costs for new programs.
-
Cash Reserves Decline
Cash and cash equivalents decreased by $3.8 million in the quarter, from $22.1 million at December 31, 2025, to $18.3 million at March 31, 2026.
Analysis · SRTS · Industrial Applications And Services
Sensus Healthcare's Q1 2026 results show a significant deterioration in financial performance, with revenue plummeting 59% year-over-year to $3.4 million and an increased net loss of $2.6 million. This follows the 8-K filed on May 7, 2026, which initially reported the revenue decline. Critically, the company disclosed that its $15 million revolving credit facility, which it was already in default on due to profitability covenants, will terminate on May 20, 2026. This termination, coming after a 2025 net loss of $7.7 million reported in the March 4, 2026 10-K, severely impacts the company's liquidity and ability to access capital, despite management's assertion of sufficient funds for the next 12 months. The substantial decline in gross profit margin from 53.0% to 29.4% further highlights operational challenges.
At the time of this filing, SRTS was trading at $3.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $57.4M. The 52-week trading range was $2.82 to $5.92. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.